RenovoRx Inc
NASDAQ:RNXT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.733
1.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
RenovoRx Inc
RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for the local treatment of solid tumors. The company is headquartered in San Jose, California and currently employs 6 full-time employees. The company went IPO on 2021-08-17. The firm is focused on developing therapies for the local treatment of solid tumors. The firm's lead product candidate RenovoGem. Its other product candidate include Renovo Trans-Arterial Micro-Perfusion (RenovoTAMP), and RenovoCath delivery system. RenovoGem, is a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath. Its therapy platform, RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) is focused on optimizing drug concentration in solid tumors using small molecule chemotherapeutics that enable physicians to isolate segments of the vascular anatomy closest to tumors and force chemotherapy across the blood vessel wall to bathe these difficult-to-reach tumors in chemotherapy.
RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for the local treatment of solid tumors. The company is headquartered in San Jose, California and currently employs 6 full-time employees. The company went IPO on 2021-08-17. The firm is focused on developing therapies for the local treatment of solid tumors. The firm's lead product candidate RenovoGem. Its other product candidate include Renovo Trans-Arterial Micro-Perfusion (RenovoTAMP), and RenovoCath delivery system. RenovoGem, is a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath. Its therapy platform, RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) is focused on optimizing drug concentration in solid tumors using small molecule chemotherapeutics that enable physicians to isolate segments of the vascular anatomy closest to tumors and force chemotherapy across the blood vessel wall to bathe these difficult-to-reach tumors in chemotherapy.
Solid Revenue Growth: Year-to-date revenue reached approximately $900,000 by Q3, with $266,000 coming in the third quarter alone, reflecting increasing commercial traction.
Commercial Expansion: RenovoCath is now approved at 14 leading cancer centers, up from 5 at the start of 2025, and 24 centers have formally requested quotes.
Lean Operations: The company has achieved this growth with a small, cost-efficient team and continues to prioritize fiscal discipline.
Clinical Progress: The Phase III TIGeR-PaC trial remains on track, with enrollment expected to finish in early 2026 and final data anticipated in 2027.
Adequate Cash Position: Over $10 million in cash and cash equivalents at quarter-end, expected to fund operations into mid-2026.
Market Focus: RenovoRx will continue to focus exclusively on the U.S. market for now due to favorable reimbursement and large opportunity.
Supply Chain Strength: The company’s manufacturing is U.S.-based, with strong partnerships and the ability to quickly ramp up production if needed.
